Aldesleukin is a laboratory-produced form of interleukin-2 (IL-2), a signaling protein that regulates the growth and activity of immune cells. It is used in cancer immunotherapy, particularly for metastatic renal cell carcinoma and metastatic melanoma. High-dose treatment can produce durable tumor responses in a minority of patients, but it can also cause life-threatening toxicity. Aldesleukin is marketed under the brand name Proleukin.
Composition and mechanism
Aldesleukin is a recombinant protein manufactured using genetically engineered Escherichia coli. It differs slightly from naturally occurring human IL-2: it lacks the initial alanine residue, contains a serine substitution for cysteine at position 125, and is not glycosylated.
IL-2 is a cytokine, a type of signaling molecule used by the immune system. By binding to IL-2 receptors, aldesleukin promotes the proliferation and activation of T cells and natural killer cells. These cells can recognize and destroy tumor cells, although immune activation does not reliably translate into tumor regression.
IL-2 also supports regulatory T cells, which restrain immune responses and help maintain immune tolerance. Its effects therefore depend on dose, receptor expression, and the surrounding immune environment. The same signaling pathway can support antitumor immunity or immune regulation under different conditions.
Established clinical uses
Metastatic kidney cancer and melanoma
In the United States, aldesleukin was approved for metastatic renal cell carcinoma in 1992 and metastatic melanoma in 1998. Metastatic disease means that cancer has undergone spread beyond its original site.
Historically, high-dose aldesleukin was notable because a small proportion of treated patients experienced complete tumor regression lasting for years. Most patients, however, did not achieve a complete response, and treatment carried substantial acute risk. Findings from carefully selected trial populations do not describe the expected outcome for every person with either cancer.
The development of immune checkpoint inhibitors and targeted cancer therapies has substantially changed treatment for both diseases. High-dose aldesleukin consequently has a more restricted role than it did before these alternatives became available.
Support for cellular immunotherapy
Aldesleukin is also used in some adoptive cell therapy regimens. In these treatments, immune cells are collected, expanded outside the body, and infused into the patient. IL-2 can support the infused cells after administration.
This use is distinct from treating a tumor with aldesleukin alone. The treatment’s activity and toxicity reflect the entire regimen, which may include preparative chemotherapy and a cellular product as well as aldesleukin.
Administration and pharmacology
Established high-dose cancer regimens administer aldesleukin by repeated intravenous infusions in a hospital. Treatment requires experienced personnel and access to intensive supportive care because physiological changes can occur rapidly. Doses may be withheld or treatment stopped when toxicity develops.
Its circulating half-life is short, and the kidneys have an important role in its clearance and metabolism. Nevertheless, its biological effects can persist beyond the period during which the administered protein remains in circulation. The intensity of immune activation and organ toxicity is therefore not determined by circulating drug concentration alone.
Adverse effects and limitations
The characteristic serious toxicity is capillary leak syndrome. Increased vascular permeability allows fluid and proteins to move from blood vessels into surrounding tissues. This can cause low blood pressure, edema, reduced organ perfusion, and impairment of respiratory, kidney, or cardiac function.
Other important risks include:
- Neurological toxicity, including confusion and altered consciousness.
- Serious infections, including sepsis.
- Cardiac arrhythmias and myocardial ischemia.
- Respiratory impairment and reduced urine output.
- Immune-mediated inflammatory disorders.
Common adverse effects include fever, chills, nausea, vomiting, diarrhea, rash, and fatigue. Severe reactions can be fatal. Significant cardiac, pulmonary, renal, hepatic, or neurological impairment can preclude high-dose treatment under prescribing criteria.
These toxicities limit the population able to receive treatment and complicate comparisons with less acutely toxic therapies.
Low-dose research
Lower-dose aldesleukin has been investigated in clinical trials for autoimmune and inflammatory disorders. The rationale is that regulatory T cells express high-affinity IL-2 receptors and may respond to lower IL-2 concentrations than those required for broad activation of other immune cells.
Investigations include conditions such as systemic lupus erythematosus and graft-versus-host disease. These approaches differ substantially from high-dose cancer treatment in their goals, schedules, and biological effects. Research findings do not establish aldesleukin as a generally approved treatment for autoimmune disease; regulatory status depends on the indication and jurisdiction.